BRCA1 and ovarian carcinoma: However, many of the currently available treatment options, such as PARP inhibitors veliparib and olaparib, are targeted agents for patients with BRCA1 and/or BRCA2 mutations and are therefore ineffective for many ovarian cancer patients [28,29].